1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene, Ltd. Announces China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

01/06/2022 | 03:30am EDT

BeiGene, Ltd. announced that the China National Medical Products Administration (NMPA) has approved BeiGene’s anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). A supplemental biologics license application for tislelizumab in this indication was previously accepted for review by the China NMPA in March 2021. The approval of tislelizumab was supported by clinical results from a randomized, open-label, global Phase 3 trial RATIONALE 303 (NCT03358875) comparing tislelizumab to docetaxel in the second- or third-line setting in patients with locally advanced or metastatic NSCLC who have progressed on prior platinum-based chemotherapy. A total of 805 patients in 10 countries across Asia, Europe, the Americas, and Oceania were enrolled in the trial, randomized 2:1 to either the tislelizumab arm or the docetaxel arm. As announced in November 2020, the trial met the primary endpoint of overall survival (OS) at the planned interim analysis, as recommended by the independent Data Monitoring Committee (IDMC). Tislelizumab was generally well-tolerated, consistent with known safety risks from previously reported results across different tumor types, with no new safety signals identified. The results of the interim analysis of the trial were presented at the American Association for Cancer Research (AACR) Annual Meeting and announced by BeiGene in April 2021.

© S&P Capital IQ 2022
All news about BEIGENE, LTD.
05/17BeiGene to Open Regional Office in Switzerland
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
05/11Asian ADRs Move Higher in Wednesday Trading
05/10Asian ADRs Climb Higher in Tuesday Trading
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
05/09INSIDER SELL : BeiGene
05/09BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 429 M - -
Net income 2022 -1 407 M - -
Net cash 2022 2 668 M - -
P/E ratio 2022 -8,83x
Yield 2022 -
Capitalization 13 526 M 13 526 M -
EV / Sales 2022 7,60x
EV / Sales 2023 5,73x
Nbr of Employees 8 300
Free-Float 99,0%
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | BGNE | US07725L1026 | MarketScreener
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 17
Last Close Price 131,09 $
Average target price 315,41 $
Spread / Average Target 141%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-51.61%13 526
GILEAD SCIENCES, INC.-12.93%79 298
WUXI APPTEC CO., LTD.-19.12%41 409
BIONTECH SE-39.08%38 169